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Abstract
Background. Few data are available about the very
long-term outcome of patients with proliferative lupus
nephritis.
Methods. Ninety-three Italian patients with biopsy-
proven proliferative lupus nephritis (15 with class III, 9
with class IIIþV, 64 with class IV and 5 with class
IVþV) followed for a median follow-up of 15 years in
a single renal unit were considered for this observa-
tional study. Patients were treated with an induction
treatment consisting of high doses of corticosteroids
plus immunosuppressive agents in the more severe
cases. This treatment was repeated in the event of a
renal flare. Then corticosteroids and immunosuppres-
sive agents were reduced to the minimal effective dose
for maintenance.
Results. Renal survival including death was 97% at
10 years and 82% at 20 years. At the last follow-up
visit, 59 patients were in complete renal remission,
18 were in partial renal remission, four patients had
chronic renal insufficiency, six had entered end-stage
renal disease and six patients had died.
At multivariate analysis the lack of achievement of
complete renal remission and the occurrence of
nephritic flares were significantly correlated both
with the risk of doubling plasma creatinine and death
or dialysis. Those patients who entered complete renal
remission had significantly less probability of develop-
ing nephritic flares.
Conclusion. The long-term prognosis of Caucasian
patients with proliferative lupus nephritis may be
better than usually thought. Favorable factors for
good long-term outcome are the achievement of
complete renal remission, the absence of nephritic
flares and their complete reversibility after therapy.
Keywords: immunosuppressive therapy; long-term
renal survival; lupus nephritis
Introduction
Renal involvement is frequent in systemic lupus
erythematosus (SLE) and may greatly influence the
course of the disease. In general, the prognosis is more
severe for patients with diffuse or focal proliferative
glomerulonephritis while the course of pure membra-
nous SLE nephritis is often considered to be more
indolent [1].
There is general agreement that proliferative lupus
nephritis deserves an aggressive treatment, particularly
when patients present with increased serum creatinine
and/or nephrotic proteinuria with high activity indices
at renal biopsy [2]. Until recently, corticosteroids and
intravenous pulses of cyclophosphamide have been the
routine treatment for patients with proliferative lupus
nephritis. This treatment appeared to improve the
probabilities of remission in comparison to cortico-
steroids alone, even when corticosteroids were given
at high doses by intravenous pulses. However, as such
a strategy often brought with it severe side effects [3]
the use of lower doses of intravenous cyclophos-
phamide followed by azathioprine began to be used as
an alternative treatment. A multicentre randomized
trial showed that the efficacy of this latter regimen was
equivalent to treatment with high-dose intravenous
cyclophosphamide. The risk of severe infections was
halved with the new regimen but the difference was not
statistically significant [4]. Another controlled trial
compared intravenous cyclophosphamide pulses plus
oral prednisone with intravenous pulses of methyl-
prednisolone plus azathioprine. After a median
follow-up of 5–7 years no difference in serum
creatinine or proteinuria between the two groups was
found [5].
There is little information about the long-term
prognosis of patients with SLE proliferative nephritis.
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Only a few studies have reported the outcome
for patients followed for 5 years or more, and in
most cases the number of patients was small.
In this paper we report the long-term outcome of
93 patients with biopsy-proven proliferative lupus
nephritis followed by a single centre for a median of
15 years and treated with a flexible strategy, mainly
based on high-dose corticosteroids and oral cytotoxic
agents for induction, followed by small doses of
prednisone and azathioprine for maintenance [6].
In this cohort of patients we also evaluated the
time-dependent predictive factors associated either
with chronic renal insufficiency or with end-stage
renal disease/death.
Subjects and methods
Participants
Of 194 patients with lupus nephritis referred to our renal unit
from practitioners or from rheumatological or immunologi-
cal units between January 1973 and December 2000, 101
Italian patients had an histological diagnosis of proliferative
nephritis, class III or class IV [7] and a potential follow-up
of at least 5 years. All the other patients but three had,
at renal biopsy, different classes of lupus nephritis or a
follow-up of <5 years. Three SLE patients admitted to our
unit in the same period for nephritic (two patients) or
nephrotic syndrome (one patient) were not submitted to
renal biopsy due to low platelet count. Eight out of the 101
patients had a creatinine clearance lower than 20ml/min at
presentation and a chronicity index higher than 8 [2] at
initial renal biopsy and were considered to have irreversible
renal failure and were excluded from the study.
At presentation, all the remaining 93 patients fit the
diagnosis of SLE according to American College of
Rheumatology criteria [8]. For the aims of this study, all
the renal biopsies were reviewed and reclassified according
to ISN/RNP classification [7]. Activity and chronicity
indices were calculated according to the score proposed by
Austin et al. [2].
Treatment
All patients were treated according to a flexible strategy,
already described elsewhere [6,9]. The philosophy of such
a strategy was to start with an induction treatment
based on high-dose corticosteroids associated with an oral
cytotoxic agent in the more severe cases or with azathio-
prine in milder cases. When the activity of the disease
was quenched, the cytotoxic agent was replaced by
azathioprine for maintenance, trying to reduce treatment
to the minimal possible doses. In selected patients a
cautious attempt of complete withdrawal was tried [10].
An induction treatment was started again in any cases of
flares of activity [9].
Definitions
– The hard end point was defined by death or the need of
chronic dialysis.
– For the other definitions we used those recently proposed
by the Renal Subcommittee of Renal insufficiency of the
American College of Rheumatology [11]:
– Renal insufficiency at presentation: serum creatinine
>1.2mg/dl and creatinine clearance lower than
75ml/min.
– Nephrotic syndrome: proteinuria >3.5 g/24 h with plasma
albumin< 3 g/dl.
– Non-nephrotic proteinuria: proteinuria between 0.21 and
3.5 g/24 h.
– Arterial hypertension: supine diastolic blood pressure
>90mmHg and/or systolic blood pressure >140mmHg in
three consecutive measurements.
– ‘Nephritic flare’: a sudden increase in plasma creatinine of
at least 30% over the last value, associated with nephritic
urinary sediment and increased proteinuria.
– ‘Proteinuric flare’: an increase in proteinuria without
modification of plasma creatinine. Proteinuria had to
increase by at least 2 g per day if the basal proteinuria was
less than 3.5 g per day, or doubled, if the patient already
had nephrotic proteinuria.
– Chronic renal insufficiency: doubling of plasma creatinine
lasting for at least 6 months with a value of plasma
creatinine of at least 2mg/dl and creatinine clearance
 40ml/min without any improvement over time.
– End-stage renal disease: the need of dialysis therapy.
– Complete renal remission: serum creatinine 1.2mg/dl,
and 25% increase of baseline creatinine clearance
if abnormal, or stable value if normal at baseline,
proteinuria <0.2 g/24 h, and inactive sediment defined as
5 red blood cells/high power field (hpf), 5 white blood
cells/hpf and no cellular casts.
– Partial renal remission: proteinuria from 0.21 to 2 g/day
and serum creatinine 1.2mg/dl, and 25% increase of
baseline creatinine clearance if abnormal, or stable value
if normal at baseline.
– The creatinine clearance has been calculated according to
Cockcroft and Gault.
– ECLAM (European Consensus Lupus Activity
Measurement) score [12] was evaluated at presentation
and at last observation (range 0–10).
Statistical methods
The statistical package S-Plus was used to analyse sample
data. Means SDs were used for descriptive analysis.
Since most of the variable distributions showed high
non-normality, median and 25% to 75% interquartile
range (IQR) were also calculated. Survival curves were
drawn using the Kaplan–Meier estimate and compared using
the log-rank test. Univariate and multivariate proportional
hazards Cox regression analysis was used to investigate the
prognostic value of continuous and binary (dichotomised)
variables. At the univariate analysis, the following variables
were tested: sex, age, months between the diagnosis of SLE
and lupus nephritis, C3 an C4 complement fractions, anti-
DNA antibody titres, white cell count, haematocrit, platelet
count, aPL antibody positivity, serum albumin, serum
creatinine, proteinuria, nephrotic syndrome, number of red
blood cell count, arterial hypertension at diagnosis of lupus
nephritis, activity and chronicity index, ECLAM score,
treatment with aspirin, anti-malarials, Ace-inhibitors/ARB
and the following time-dependent factors: persistence of
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arterial hypertension, occurrence of complete renal remission
and of nephritic flares, or of proteinuric flares. As statins
were administered to a few patients only in recent years
we could not evaluate their statistical power. For the
multivariate analysis no automatic selection process was
used, due to the limited size of the sample. All the
variables that were significant at univariate analysis were
included. After finding the independent predictors, also the
variables that were not significant at univariate analysis
were tested.
Relative risks and their 95% confidence intervals were
derived, after fitting the Cox proportional hazard model, as
the antilogarithm of the coefficient estimated for each
covariate.
Results
Characteristics of the patients (Table 1)
Ninety-three Italian patients with biopsy-proven
proliferative lupus nephritis (15 with class III, 9 with
class IIIþV, 64 with class IV and 5 with class IVþV)
and a minimal potential follow-up of at least 5 years
were considered for this observational study. The
median age at presentation of lupus nephritis was
27.3 years (IQR 21–33.4). Eight patients were
males and 85 females. The median duration of SLE
before the diagnosis of lupus nephritis was 1 month
(IQR 0–29). SLE and lupus nephritis were diag-
nosed in 45 patients at the same time. The median
duration between the diagnosis of lupus nephritis
and the beginning of the therapy was 2 months
(IQR 0.9–7.1).
At presentation of lupus nephritis 44 patients (47%)
had renal insufficiency (median serum creatinine
1.6mg/dl, (IQR 1.32–2.25mg/dl); median creatinine
clearance 43.9ml/min, (IQR 33.0–57.8ml/min) asso-
ciated in 28 patients with nephrotic syndrome (median
proteinuria 5.6 g/24 h; IQR 4.4–7.7 g/24 h) and with
non-nephrotic proteinuria in the other 16 patients
(median proteinuria 1.9 g/24 h; IQR 1.8–2.8 g/24 h).
The remaining 49 patients (53%) had normal renal
function, with nephrotic syndrome in 21 (median
proteinuria 5.0 g/24 h, IQR 4.6–6.1 g/24 h) and non-
nephrotic proteinuria (median 2.1 g/24 h, IQR 1.3–2.8/
24 h) in 28 patients. All patients had microscopic
haematuria (median number of erythrocytes 15/hpf
IQR 7–40). Sixty patients had arterial hypertension.
C3 and C4 complement fractions were low, respec-
tively, in 80 and 75 patients, 87 patients had positive
anti-DNA antibodies and 16 had positive antiphos-
pholipid antibodies. In 57 patients haematocrit was
below 35%, in 13 patients platelet count was below
150 000/mmc, and in 20 patients white blood cell count
was below 4000/mmc.
At renal biopsy the median value of activity and
chronicity index were respectively 8 (IQR 5.0–10.5)
and 2 (IQR 1–3). Fifty-four patients had been treated
with ACE-inhibitors/ARB, 14 with aspirin and 27 with
anti-malarials.
The following extra-renal manifestations of SLE at
presentation of lupus nephritis were exhibited: arthritis
in 69 patients (74.2%), skin involvement in 60 patients
(64.5%), fever in 56 patients (60%), lymphoadeno-
pathy in 18 patients (19,3%), serositis in 17 patients
(18.3%), cerebritis in six patients (6.4%). The median
ECLAM score was 6 (IQR 4–7).
Therapy
Induction treatment. Eighteen patients were treated
with oral prednisone 1–2mg/kg per day in a single
morning administration for 1 month then gradually
reduced to the maintenance. The other 75 patients
started therapy with a methylprednisolone pulse of
0.5–1 g/day for three consecutive days followed by oral
prednisone 0.5–1mg/kg/day for 1–2 months then
gradually reduced to the maintenance. In 75 patients
(81%) with plasma creatinine higher than 1.2mg/dl
and/or proteinuria higher than 5 g/day and or activity
index >5 an immunosuppressive agent was added
to the steroids: in 45 patients cyclophosphamide
1.5–2mg/kg/day was given for a median period of
3 months (IQR 2–4), in 10 patients chlorambucil
0.15–0.2mg/kg/day for a median period of 3 months
(IQR 2–3.8), and 20 patients azathioprine 2mg/kg/day
for a median period of 13.5 months (IQR 7.3–28).
Such an induction therapy was repeated in the case of
renal flares [9].
The clinical characteristics of patients treated with
steroids alone, steroids plus n cyclophosphamide/
chlorambucil and steroids plus azathioprine are
reported in Table 1.
Maintenance. Depending on the improvement of
renal and extra-renal signs and symptoms, prednisone
was progressively tapered until reaching a dose of
Table 1. Clinical and histological characteristics at presentation of
patients according to the initial therapeutical strategy
Steroids
(18 patients)
Cyclophosphamide/
Chlorambucil
(55 patients)
Azathioprine
(20 patients)
Serum creatinine
(mg/dl)
1 (0.8–15) 1.3 (0.9–2.5) 1 (0.8–1.8)
Proteinuria (g/24 h) 3.4 (2–4.8) 5 (2.5–6) 3.9 (2.2–4.6)
Creatinine
clearance
(ml/min)
74 (58–98) 69 (48.9–91) 71 (34–97)
Urinary
erythrocyte
(n8/hpf)
15 (7–40) 20 (8–40) 15 (5–40)
C3 (mg/dl) 52 (35–90) 53 (45–66) 50 (50–60)
C4 (mg/dl) 10.5 (7–2.5) 10 (5–14) 10.5 (5–19)
ECLAM score 5 (4–7) 6 (5–8) 5.5 (4–7)
Activity index 6 (4–10) 8 (6–11) 6.5 (4.2–9.7)
Chronicity index 1 (1–3) 2 (0–3) 2 (1–3)
Haematocrit (%) 35 (30–40) 32 (29–36) 33 (27.5–37)
Arterial
hypertension
(% of patients)
38% 69% 75%
If not otherwise specified, the numbers are the median values and
(interquartile ranges).
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10mg per day. A further reduction was attempted in
patients who reached a complete renal remission. After
induction, cyclophosphamide and chlorambucil
were replaced with azathioprine in 25 patients
(1–1.5mg/kg/day) for a median period of 14 months
(IQR 8–35) with cyclosporine in three patients and
with mycophenolate mofetil in two patients, while the
other 25 continued with prednisone alone. Patients
who were given azathioprine for induction continued
with azathioprine for maintenance at doses ranging
between 1.0 and 1.5mg/kg/day. In 32 patients both
corticosteroids and immunosuppressive agents were
completely withdrawn. Fifteen patients (Group 1)
never developed lupus flares. The other 17 patients
(Group 2) developed lupus flares in mean 55.8þ 58.3
months after stopping therapy and were again treated.
At the last follow-up (184.9þ 81.4 months after
withdrawal of therapy) 12 patients from group 1
were in complete remission, two patients had mild
proteinuria and one patient died. In group 2, one
patient died, 14 patients were in complete remission,
one patient had mild proteinuria and in another
patient serum creatinine doubled [10].
Outcome
Patients were followed for a median period of 181
months (IQR 97–251 months). A complete renal
remission was attained in 76 (82%) patients after a
median follow-up of 14 months (IQR 7.4–43.2) from
the beginning of the induction therapy. Among the
clinical and histological characteristics at presentation,
the only predictors of complete renal remission were
age at study entry (mean 29.3þ 10.1 years in patients
who attained complete renal remission vs 23.9þ 8.45
years in patients who did not P¼ 0.01) and the longer
duration of systemic lupus before the diagnosis of
lupus nephritis (mean 29.5þ 49.5 months in patients
who attained complete renal remission vs 5þ 11.4
months in patients who did not P¼ 0.04).
Nephritic flares occurred in 28 patients (15 patients
one flare, 7 patients two flares and 6 patients three or
more flares) after a median follow-up of 47 months
(IQR 12–114) from the beginning of the induction
therapy. Proteinuric flares occurred in 46 patients (21
patients one flare, 12 patients two flares, 13 patients
three or more flares) after a median period of 50.1
months (IQR 32.3–73) from the beginning of the
induction therapy. Fourteen patients had both protein-
uric and nephritic flares. Taken together, 60 patients
out of 93 (64%) developed at least one renal flare
during a 15-year follow-up.
Chronic renal insufficiency developed in 14 patients
(15%) after a median follow-up of 141.2 months (IQR
96.6–232.0) The risk of developing chronic renal
insufficiency was 10% at 10 years, 14% at 15 years
and 17% at 20 years (Figure 1). Among the 14 patients
who developed chronic renal insufficiency, six reached
end-stage renal disease 154 months (IQR 118–175)
after the diagnosis of lupus nephritis.
Six patients died after a median follow-up of 231
months (IQR 205–325). Of them, two were in partial
remission and four had chronic renal insufficiency. The
patient survival was 100% at 15 years and 92% at
20 years. The latest report of the Statistical Italian
Institute (ISTAT) gives a life expectancy at 20 years of
97% for Italian women aged 28 years. The causes
of deaths were malignant neoplasia in two patients,
cerebral haemorrhage in two patients, myocardial
infarct in one patient and cachexia in the last patient.
Three other patients died after the beginning of chronic
dialysis. Altogether 12 patients, of whom 10 of the 14
with chronic renal insufficiency, reached the hard
end-point (death and/or end-stage renal disease)
(Figure 1).
At the last observation, 59 patients (63,4%) were in
complete renal remission, 18 (19,3%) were in partial
renal remission, four (4.5%) had chronic renal
insufficiency, six (6.4%) entered end-stage renal disease
and six patients (6.4%) died. The median ECLAM
score at last observation was 1 (IQR 0–1). The renal
survival, including death, was 97% at 10 years, 92% at
15 years and 82% at 20 years (Figure 1).
When we divided our patients into two survival
cohorts, those presenting with lupus nephritis between
1973 and 1986 (41 patients) and those diagnosed
between 1987 and 2000 (51 patients), no differences in
survival between the two cohorts emerged for survival
without ESRD or death. The probability of doubling
serum creatinine was significantly lower in patients
diagnosed between 1987 and 2000 (98% at 10 years) in
comparison to those diagnosed between 1973 and 1986
(85% at 10 years, P¼ 0.00012).
The main side-effects and complications are
the following: infections requiring hospitalization,
15 patients (16%); herpes zoster, 16 patients (17%);
minor infections, two patients (2.1%); ovarian failure
(defined as the occurrence of menopause before
40 years), 10 patients (11%); bone aseptic necrosis,
5 patients (5.3%); osteoporosis, 12 patients (13%);
myocardial infarction and/or cerebral thrombosis,
12 patients (13%). Four malignancies occurred: one
70
80
90
100
0 5 10 15 20
years
98%
82%
90%
97%
86%
92%
83%
98%
%
Survival without chronic renal insufficiency
Survival without hard end-point
Fig. 1. Survival without doubling serum creatinine and survival
without dialysis and/or death.
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lung cancer, one thyroid cancer, one breast cancer and
one uterine cancer.
Predictors of outcome
The renal survival including death was 100% at 10 and
at 15 years and 85% at 20 years for patients with class
III and 96% at 10 years, 89% at 15 years and 82%
at 20 years in patients with class IV lupus nephritis.
There was no significant difference in the renal or
patient survival at any time point between patients
with class III and patients with class IV lupus nephritis
at initial biopsy.
Among the clinical characteristics at presentation
only serum creatinine >1.5mg/dl (P¼ 0.01), low
haematocrit (P¼ 0.04) and arterial hypertension
(P¼ 0.01) were predictive of the development of the
doubling of serum creatinine (Table 2).
The risk of doubling serum creatinine was related
to the persistence of arterial hypertension (P¼ 0.04),
the lack of achievement of complete renal remission
(P¼ 0.0000006) (Figure 2) and the development of
nephritic flares (P¼ 0.000005) (Figure 3). Chronic renal
insufficiency developed in 13 out of the 28 patients
(46%) in whom nephritic flares occurred. The number
of nephritic flares was also significantly correlated
with the development of chronic renal insufficiency.
Of the 13 patients who had more than one nephritic
flare, 10 developed chronic renal insufficiency and
only three maintained normal renal function, while of
the 15 patients with one nephritic flare, only three
doubled serum creatinine (P¼ 0.0001). The response to
therapy was assessed at 3 months. Serum creatinine
returned to the basal value in 77% of patients who
eventually maintained normal renal function and
in 16% of patients who developed chronic renal
Table 2. Characteristics of patients and their prognostic value on the development of chronic renal insufficiency (doubling of serum
creatinine)
Characteristics of patients at presentation
All 93 patients 79 pts with
normal renal function
at the last observation
14 pts with
doubling serum
creatinine at the
last observation
P
Age (years) median (IQR) 27.3 (21; 33.7) 27.26 (21.4;33.7) 27 (18.93;29.24) ns
Sex (male/female) 8/85 5/74 3/11 ns
Months between SLE and LN
diagnosis median (IQR)
1 (0; 29) 2 (0;32) 0 (0;2.8) ns
Serum creat. (mg/dl) median (IQR) 1.1 (0.8;1.6) 1 (0.8;1.5) 1.65 (1.1;2.2) ns
Serum creat.> 1.5mg/dl n8 of pts 27 18 9 0.01
GFR (ml/min) median (IQR) 69 (47.3; 90.4) 72.5 (53.2;100) 50.6 (34.8;75) ns
Proteinuria g/24 h median (IQR) 4 (2.3;5.4) 3.99 (2.3;5.5) 4 (2.5;4.7) ns
Urinary RBCn8/hpf median (IQR) 15 (7;40) 15 (5;40) 22.5 (15; 40) ns
Ser.albumin gr/dl median (IQR) 2.8 (2.3; 3.5) 2.9 (2.4;3.5) 2.4 (2.3; 3.07) ns
Anti-DNA (pos/neg) 82/6 69/5 13/1 ns
aPL (pos/neg) 14/63 11/54 3/9 ns
C3 mg/dl median (IQR) 52 (45;64) 52 (45;64) 51.5 (50;59) ns
C4 mg/dl median (IQR) 10 (5;14) 11 (6;14.5) 7 (5;12) ns
White cells/mmc median (IQR) 5600 (4000;7225) 5550 (3975;6750) 6050 (4700;7850) ns
Hematocrit% median (IQR) 33 (29;37) 33.4 (30;37) 29.5 (25;31.7) 0.04
Platelets/mmc median (IQR) 239000 (168000;305750) 241000 (166750;301250) 224500 (181000;308250) ns
ECLAM 6 (4;7) 6 (4;7) 6.5 (5.2;7) ns
Hypertension (yes/no) 60/32 47/31 13/1 0.04
Activity index median (IQR) 8 (5;10.5) 8 (5;10) 7.5 (5.2;11.7) ns
Chronicity index median (IQR) 2 (1; 3) 2 (1;3) 2(0.25;3.7) ns
Supportive therapy during the follow-up
ACE-inhibitors/ARB (yes/no) 54/39 44/35 10/4 ns
Aspirin (yes/no) 14/79 10/69 4/10 ns
Anti-malarials (yes/no) 27/66 26/53 1/13 ns
IQR, interquartile range; LN, lupus nephrits; Creat., creatinine; GFR, glomerular filtration rate; RBC, red blood cells; hpf, high power field.
P value refers to the statistical significance of the variables either in the Cox proportional hazard regression (for a continuous variable) or in
the log-rank test for survival curves difference (for a discrete or discretized variable).
40
60
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Pts who did not achieve complete renal remission
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p=0.0000006
100% 96%
90%
88%
65%
41%
%
Fig. 2. Survival without doubling serum creatinine in patients
who achieved and in those who did not achieve complete remission.
Pts, patients.
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insufficiency (P¼ 0.0001). Patients who reached com-
plete renal remission had significantly lower probability
of developing nephritic flares (Figure 4). At 20 years,
the probability of survival without nephritic flares was
71% in patients who reached complete renal remission
and 23% in patients who never reached complete renal
remission (P¼ 0.0002).
At multivariate analysis, the lack of achievement of
complete renal remission (P¼ 0.01) and the develop-
ment of nephritic flares (P¼ 0.01) were the only
independent predictors of development of chronic
renal insufficiency. The lack of achievement of
complete renal remission increased the risk of chronic
renal insufficiency by a factor of 4.3 (CI 1.4–13.4).
Nephritic flares increased the risk of development
of chronic renal insufficiency by a factor of 13.8
(CI 1.7–113).
Among the clinical characteristics at presentation,
only the chronicity index (P¼ 0.04) was predictive of
end-stage renal disease and/or death (Table 3). Among
the time-dependent risk factors, the development of the
hard end-point was significantly correlated with the
lack of achievement of complete renal remission
(P¼ 0.002) and with nephritic flares (P¼ 0.008).
Discussion
The prognosis of lupus nephritis has improved over the
years. By reviewing the published literature, Cameron
40
60
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100
0 5 10 15 20
Pts who did not develop nephritic flares
Pts who deveopednephritic flares
Years
100% 98%
93%
98%
77%
55%
p= 0.000005
%
Fig. 3. Survival without doubling serum creatinine in patients who
developed and in those who did not develop nephritic flares.
20
40
60
80
100
0 5 10 15 20
Pts who achieved complete renal remission
Pts who did not achieve complete renal remission
Years
P=0.0002
%
86% 81%
71%
65%
46%
23%
Fig. 4. Probability of not developing nephritic flares in patients who
achieved or not complete renal remission.
Table 3. Prognostic power of the characteristic of the patients to predict the development of the hard end-point (end-stage renal disease
or deaths)
Characteristics of patients at presentation
Patients alive with functioning kidney Patients in chronic dialysis or deceased P
Age (years) median (IQR) 26.7 (21;33.7) 27.8 (21.1;30.6) ns
Sex (male/female) 5/76 3/9 ns
Months between SLE and
LN diagnosis median (IQR)
1(0;29.1) 1 (0;3.9) ns
Serum creat. (mg/dl) median (IQR) 1 (0.8;1.5) 1.8 (1.5;2.4) ns
GFR (ml/min) median (IQR) 72.5 (55.2;99) 38.8 (34; 69.9) ns
Proteinuria (g/24 h) median (IQR) 4 (2.6;5.4) 2.7 (1.3;4.5) ns
Urinary RBC n8/hpf) median (IQR) 15 (5;40) 35 (15; 40) ns
Serum albumin (g/dl) median (IQR) 2.9 (2.4;3.5) 2.6 (2.1;3.1) Ns
Anti-DNA (pos/neg) 71/6 11/0 ns
aPL (pos/neg) 10/57 4/6 0.07
C3 mg/dl median (IQR) 52.5(45;64) 50 (50;57) ns
C4 mg/dl median (IQR) 10 (6;14) 10 (5;12.3) ns
White cells/mmc median (IQR) 5600 (3900;6800) 6500 (4800;7700) ns
Hematocritt% median (IQR) 33 (29;37) 31.4 (27.9;35.3) ns
Platelets/mmc median (IQR) 241000 (167250;303750) 224500 (192000;317000) ns
ECLAM score 6 (4;7) 6.5 (5;7) ns
Hypertension yes/no 51/29 9/3 ns
Activity index median (IQR) 8 (5;10) 8.5 (6;12) ns
Chronicity index median (IQR) 2 (0.5;3) 2.5(1;4.75) 0.04
Supportive therapy during the follow-up
ACE-inhibithors (yes/no) 46/35 8/4 ns
Aspirin (yes/no) 11/70 3/9 ns
Anti-malarials (yes/no) 26/55 1/11 ns
IQR, interquartile range; LN, lupus nephrits; Creat, creatinine; GFR, glomerular filtration rate; RBC, red blood cells; hpf, high power field.
P value refers to the statistical significance of the variables either in the Cox proportional hazard regression (for a continuous variable) or in
the log-rank test for survival curves difference (for a discrete or discretized variable).
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[13] found that life expectancy at 5 years increased
from 44% in the period 1953–1969 to 82% in the
period 1980–1995. Derksen et al. [14] reported a
mortality of 11,2% after a mean follow-up of 53
months in 56 patients with biopsy-proven lupus
nephritis, of whom 38 with proliferative lupus nephri-
tis. Nossent et al. [15] reported a survival of 82% at 15
years in 26 patients with proliferative lupus nephritis.
Few papers have reported the long-term renal outcome
in patients with lupus nephritis [13,16,17]. With one
exception [17], in those reports not only patients with
proliferative glomerulonephritis, but also patients
with other subtypes of lupus nephritis were included.
In this study we selected patients with biopsy-proven
type III or type IV lupus nephritis and with a potential
follow-up of at least 5 years. The only criterion of
exclusion was the presence of irreversible renal failure,
defined by a creatinine clearance lower than 20ml/min
associated with an elevated chronicity index at renal
biopsy. We were able to recruit 93 patients who were
followed for a median of 15 years, the longest
follow-up for such a typology of patients, to the best
of our knowledge. About half of our patients had
some degree of renal dysfunction at presentation.
The expected patient survival at 20 years was 92%.
The renal survival, including death, was 97% at
10 years and 82% at 20 years. These data show that
the renal prognosis of proliferative lupus nephritis
may be considerably better than generally estimated,
at least in Caucasian patients.
A number of factors may account for this good
prognosis. The choice of the therapeutic strategy may
have had an important role. Two main causes of renal
failure or death in lupus nephritis patients are an over-
treatment which causes severe and life-threatening
morbidity or an under-treatment which causes a
silent, progressive kidney dysfunction and other
extra-renal complications of SLE. In an attempt to
avoid either of these risk factors we have used since the
early 70s an aggressive, but relatively short treatment
for induction and flares, while reducing to the minimal,
effective dosage corticosteroids and immunosuppres-
sive drugs whenever the activity of lupus nephritis was
quenched. However, even this strategy may lead to
over- or under-treatment, as assessing whether lupus
nephritis is active or inactive is not always easy. To
minimize this risk we have created a small task force of
nephrologists dedicated to the follow-up of SLE
patients. Moreover, patients were asked to come
regularly to our unit for laboratory and clinical
check-up, this program being made possible by the
fact that until recently the laboratory tests and the
clinical visits in hospital were free of charge in Italy.
Another point of paramount importance was the fact
that doctors following SLE patients were available
by phone for any problem or query of the patient.
Patients who did not present at regular visits were
interviewed by phone in order to check their adherence
to treatment. This strict surveillance probably allowed
a prompt diagnosis and treatment and probably
reduced the impact of another important risk factor
for SLE patients, poor compliance. However, we
cannot know whether such a therapeutical policy
may also provide satisfactory results in other popula-
tions at a higher risk (i.e. African American, Hispanic)
or in other settings where it is difficult to organize a
task force of nephrologists devoted to lupus nephritis.
In this series the risk of death or end-stage renal
failure was particularly elevated in the 14 patients who
showed a persistent doubling of serum creatinine.
Four of them died, six developed end-stage renal
failure and three of them eventually died after starting
chronic dialysis. The other two deaths occurred many
years after admission in patients with partial remission.
While the risk of renal failure in patients with increased
serum creatinine speaks for itself, the unfavourable
impact of renal dysfunction on patient survival is not
unexpected in view of the recent evidence showing an
increased risk of cardiovascular disease and other
life-threatening complications in patients with renal
insufficiency [18].
The risk of developing renal insufficiency was higher
in patients who presented with serum creatinine higher
than 1.5mg/dl and/or hypertension, similarly to that
which was reported by other investigators [2]. We also
found a prognostic role for anaemia, a risk factor
which was already pointed out by Austin et al. [2] and
confirmed in our previous studies [9]. The available
data do not explain whether anaemia simply reflected
the association with renal dysfunction or actually
represented an independent risk factor. However,
treating anaemia may be advisable in SLE patients,
also taking into account recent data showing that
anaemia may be considered as a risk factor for
cardiovascular disease [19]. Among the clinical and
histological characteristics at presentation, the only
significant risk factor for end-stage renal failure or
death was a high chronicity index at initial renal
biopsy. The prognostic role of this parameter has been
evaluated by previous analyses in different ways. Some
investigators reported that chronicity index repre-
sented a significant risk factor, [1,2] while others did
not [20]. It is likely that those results were influenced
by the differing severity of chronic lesions in different
series. At any rate, there is little doubt that diffuse
interstitial fibrosis, tubular atrophy and glomerular
sclerosis are associated with a poor outcome, empha-
sizing the importance of an early diagnosis and
treatment of SLE nephritis.
The analysis of time-dependent variables showed
that two factors were significantly associated with the
risk of developing renal insufficiency or hard end-
points, i.e. the lack of complete renal remission and the
occurrence of nephritic flares. Recent papers have
pointed out the importance of complete remission in
preventing the development of renal insufficiency [4].
The deleterious role of nephritic flares has been already
demonstrated by us [9] and then confirmed by other
investigators. The present data confirm our previous
results and underline for the first time the importance
of the achievement of complete renal remission
in preventing the development of nephritic flares.
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Our data also show that the risk of renal function
deterioration is significantly higher in patients who
experienced two or more flares than in patients with a
single flare. Taken together, these data show the
importance of quenching the renal activity of SLE.
On the other hand, a protracted immunosuppressive
therapy is likely to render SLE patients more
susceptible to invalidating and even life-threatening
side-effects. To control flares while avoiding a vigorous
immunosuppressive therapy in the long term, we
limited an aggressive treatment to established flares
and submitted the patients to frequent clinical and lab
monitoring to identify renal activity as soon as
possible.
Most patients reached complete renal remission of
renal disease. This happened after a median period
of 14 months, a time similar to that observed in other
series using different therapeutical schedules [4].
As already pointed out, we found that serum creatinine
improved soon after beginning induction therapy,
while the recovery of proteinuria occurred later.
We decided not to increase induction or maintenance
therapy to accelerate the remission of proteinuria in
order not to increase the risk of iatrogenic morbidity.
It is difficult to know whether a more aggressive
therapy would have resulted in an earlier remission of
proteinuria or an increased rate of severe side effects.
At any rate, we continued our policy, having observed
a high rate of complete renal remission.
During this long-term follow-up, about 30% of
patients developed at least one nephritic flare which
required further vigorous treatment. As mentioned
above, patients who developed flares had a higher
probability of developing renal insufficiency. On the
other hand, most patients who completely recovered
after treatment did not develop chronic renal insuffi-
ciency. This would mean that rather than trying to
prevent flares with too aggressive a therapy, that may
be associated with severe and life-threatening side
effects, it might be better to reduce the doses of
corticosteroids and immunosuppressive drugs for
maintenance, while implementing clinical surveillance
and being ready to increase treatment whenever signs
of activity appear. In our experience such a strategy
resulted in relatively few complications and also in
a low mortality.
In conclusion, the retrospective analysis of this series
shows that the long-term prognosis of Caucasian
patients with SLE proliferative nephritis may be
better than generally thought, if patients are referred
to nephrologists before irreversible renal damage has
already set in. We feel that treatment of lupus nephritis
should be flexible so as to avoid the risks of over- or
under-immunosuppression. Incomplete recovery from
renal flares being an important risk factor for
progression, we strongly recommend that patients are
regularly followed by well-trained physicians and that
flares are treated promptly and vigorously until serum
creatinine returns to baseline values. On the other
hand, to minimize iatrogenic morbidity, the doses of
steroids and immunosuppressive agents should be
slowly reduced to the minimal effective dosage in
patients with inactive disease.
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